433 related articles for article (PubMed ID: 22672081)
1. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
2. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
4. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
[TBL] [Abstract][Full Text] [Related]
5. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
7. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
8. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
9. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal.
Gross JL; Rojas A; Shah S; Tinahones FJ; Cleall S; Rodríguez A
Curr Med Res Opin; 2016 Jun; 32(6):1109-16. PubMed ID: 26934128
[TBL] [Abstract][Full Text] [Related]
11. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
12. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study.
Raccah D; Haak TJ; Huet D; Monnier L; Robertson D; Labard P; Soler J; Penfornis A
Diabetes Metab; 2012 Dec; 38(6):507-14. PubMed ID: 23116646
[TBL] [Abstract][Full Text] [Related]
13. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
14. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
15. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
16. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
[TBL] [Abstract][Full Text] [Related]
18. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes].
Fernández Landó L; Massari F; Oviedo A; Jiang H
Medicina (B Aires); 2012; 72(3):235-42. PubMed ID: 22763161
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
20. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
